Literature DB >> 33971970

Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment.

Linbang Wang1, Tao He1, Jingkun Liu2, Jiaojiao Tai2, Bing Wang3, Zhiyu Chen1, Zhengxue Quan4.   

Abstract

BACKGROUND: Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME). However, their contribution to the immunosuppressive status of the TME remains unclear.
METHODS: We integrated single-cell sequencing and transcriptome data from different tumor types to uncover the molecular features of TAMs. In vitro experiments and prospective clinical tests confirmed the results of these analysis.
RESULTS: We first detected intra- and inter-tumoral heterogeneities between TAM subpopulations and their functions, with CD86+ TAMs playing a crucial role in tumor progression. Next, we focused on the ligand-receptor interactions between TAMs and tumor cells in different TME phenotypes and discovered that aberrant expressions of six hub genes, including FLI1, are involved in this process. A TAM-tumor cell co-culture experiment proved that FLI1 was involved in tumor cell invasion, and FLI1 also showed a unique pattern in patients. Finally, TAMs were discovered to communicate with immune and stromal cells.
CONCLUSION: We determined the role of TAMs in the TME by focusing on their communication pattern with other TME components. Additionally, the screening of hub genes revealed potential therapeutic targets.

Entities:  

Keywords:  FLI1; Intercellular communication; Tumor microenvironment; Tumor-associated macrophages

Year:  2021        PMID: 33971970     DOI: 10.1186/s40164-021-00226-1

Source DB:  PubMed          Journal:  Exp Hematol Oncol        ISSN: 2162-3619


  53 in total

Review 1.  Macrophages and Metabolism in the Tumor Microenvironment.

Authors:  Ilio Vitale; Gwenola Manic; Lisa M Coussens; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Metab       Date:  2019-07-02       Impact factor: 27.287

Review 2.  Understanding the tumor immune microenvironment (TIME) for effective therapy.

Authors:  Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel
Journal:  Nat Med       Date:  2018-04-23       Impact factor: 53.440

Review 3.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy.

Authors:  Yoshihiro Komohara; Yukio Fujiwara; Koji Ohnishi; Motohiro Takeya
Journal:  Adv Drug Deliv Rev       Date:  2015-11-24       Impact factor: 15.470

4.  BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer.

Authors:  Víctor G Martínez; Carolina Rubio; Mónica Martínez-Fernández; Cristina Segovia; Fernando López-Calderón; Marina I Garín; Alicia Teijeira; Ester Munera-Maravilla; Alberto Varas; Rosa Sacedón; Félix Guerrero; Felipe Villacampa; Federico de la Rosa; Daniel Castellano; Eduardo López-Collazo; Jesús M Paramio; Ángeles Vicente; Marta Dueñas
Journal:  Clin Cancer Res       Date:  2017-09-19       Impact factor: 12.531

Review 5.  Targeting tumor-associated macrophages in head and neck squamous cell carcinoma.

Authors:  Bolei Li; Min Ren; Xuedong Zhou; Qi Han; Lei Cheng
Journal:  Oral Oncol       Date:  2020-04-18       Impact factor: 5.337

6.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Authors:  Adil I Daud; Jedd D Wolchok; Caroline Robert; Wen-Jen Hwu; Jeffrey S Weber; Antoni Ribas; F Stephen Hodi; Anthony M Joshua; Richard Kefford; Peter Hersey; Richard Joseph; Tara C Gangadhar; Roxana Dronca; Amita Patnaik; Hassane Zarour; Charlotte Roach; Grant Toland; Jared K Lunceford; Xiaoyun Nicole Li; Kenneth Emancipator; Marisa Dolled-Filhart; S Peter Kang; Scot Ebbinghaus; Omid Hamid
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 7.  Macrophages and cancer: from mechanisms to therapeutic implications.

Authors:  Renato Ostuni; Franz Kratochvill; Peter J Murray; Gioacchino Natoli
Journal:  Trends Immunol       Date:  2015-03-11       Impact factor: 16.687

8.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

9.  Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.

Authors:  Sören Müller; Gary Kohanbash; S John Liu; Beatriz Alvarado; Diego Carrera; Aparna Bhaduri; Payal B Watchmaker; Garima Yagnik; Elizabeth Di Lullo; Martina Malatesta; Nduka M Amankulor; Arnold R Kriegstein; Daniel A Lim; Manish Aghi; Hideho Okada; Aaron Diaz
Journal:  Genome Biol       Date:  2017-12-20       Impact factor: 13.583

Review 10.  Tumor-associated macrophages: an accomplice in solid tumor progression.

Authors:  Yibing Chen; Yucen Song; Wei Du; Longlong Gong; Haocai Chang; Zhengzhi Zou
Journal:  J Biomed Sci       Date:  2019-10-20       Impact factor: 8.410

View more
  10 in total

1.  Dissecting Immunosuppressive Cell Communication Patterns Reveals JunB Proto-Oncogene (JUNB) Shaping a Non-Inflamed Tumor Microenvironment.

Authors:  Hualin Chen; Gang Chen
Journal:  Front Genet       Date:  2022-06-24       Impact factor: 4.772

Review 2.  Deciphering Innate Immune Cell-Tumor Microenvironment Crosstalk at a Single-Cell Level.

Authors:  Ryohichi Sugimura; Yiming Chao
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 3.  Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.

Authors:  Mohammad Javed Ansari; Dmitry Bokov; Alexander Markov; Abduladheem Turki Jalil; Mohammed Nader Shalaby; Wanich Suksatan; Supat Chupradit; Hasan S Al-Ghamdi; Navid Shomali; Amir Zamani; Ali Mohammadi; Mehdi Dadashpour
Journal:  Cell Commun Signal       Date:  2022-04-07       Impact factor: 5.712

4.  SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.

Authors:  Hui Yang; Meimei Yan; Wei Li; Linping Xu
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

Review 5.  Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.

Authors:  Shuangli Zhu; Ming Yi; Yuze Wu; Bing Dong; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2021-12-29

6.  Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing.

Authors:  Yue Shi; Qi Zhang; Hai Bi; Min Lu; Yezhen Tan; Daojia Zou; Liyuan Ge; Zhigang Chen; Cheng Liu; Weimin Ci; Lulin Ma
Journal:  Genome Biol       Date:  2022-03-31       Impact factor: 13.583

7.  Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at the single-cell transcriptome level.

Authors:  Danfeng Zhang; Yadan Li; Chunyan Du; Lina Sang; Liu Liu; Yingmei Li; Fang Wang; Wenjuan Fan; Ping Tang; Sidong Zhang; Dandan Chen; Yanmei Wang; Xiaoyi Wang; Xinsheng Xie; Zhongxing Jiang; Yongping Song; Rongqun Guo
Journal:  J Transl Med       Date:  2022-08-12       Impact factor: 8.440

Review 8.  Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.

Authors:  Yuheng Yan; Lan Huang; Yiming Liu; Ming Yi; Qian Chu; Dechao Jiao; Kongming Wu
Journal:  J Hematol Oncol       Date:  2022-08-10       Impact factor: 23.168

9.  Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Linping Xu; Meimei Yan; Jianpeng Long; Mengmeng Liu; Hui Yang; Wei Li
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

Review 10.  Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.

Authors:  Yuze Wu; Ming Yi; Mengke Niu; Qi Mei; Kongming Wu
Journal:  Mol Cancer       Date:  2022-09-26       Impact factor: 41.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.